CRL

NEUTRALEarnings

Charles River Laboratories Inte

2026-08-26

Price

$295.10

-0.85%

This is the 2026-08-26 snapshot — the signals and analysis for CRL as of this single trading day.

View full CRL research hub →

Score3.8Watchlist

Signals4/8 DNA1/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume1.4xvs 20d avg

Analysis

Charles River Laboratories (CRL) is experiencing High-Conviction Price Discovery because of its recent Q2 earnings beat, raised 2026 guidance, and a newly announced vaccine collaboration with Medigen. These fundamental catalysts are validated by flawless technical signals, including a PERFECT_STACK and a GOLDEN_CROSS, which show strong institutional accumulation of shares. With a highly supportive RISK_ON macro regime featuring low high-yield credit spreads and a normalized VIX, conviction remains extremely high that CRL's +19.7% relative strength will continue to drive market outperformance.

Fired Signals

ALPHA MALEGOLDEN CROSSMARKET LEADERPERFECT STACKBARGAIN HUNTERCHURNING

Key Takeaways

Actionable Thesis: Buy CRL to capture momentum from its raised guidance and bullish analyst revisions, supported by elite technical leadership.
Key Risk: Profit-taking near the $300 psychological resistance or a sudden macroeconomic shock to biotech funding.
What to Watch: Price action around the $300 level for a breakout, utilizing the $230.87 support as a strict risk-management pivot.

← Back to 2026-08-26 View Full CRL History →Yahoo Finance &nearr;